UK MedTech firms are seeing a clear shift in how regulators assess medical devices, and many companies are now paying close attention to recent moves by the MHRA and the FDA. The MHRA is showing interest in how the United States authorises devices, while more UK manufacturers are beginning to review whether they should prepare for FDA compliance medical devices when planning entry into the U.S. market. These developments signal that the regulatory approach may start to change for device makers, software developers and distributors.

For UK businesses, this could influence how products are approved, labelled and monitored in different regions. It may also shape how companies plan their documentation, technical files and long-term market access strategies.

How The MHRA and FDA are Shifting Their Approach

The MHRA has been reviewing how the United States evaluates and authorises medical devices, and this has caught the attention of UK manufacturers. The FDA’s approach to device approval, documentation and post-market duties is becoming more relevant as UK regulators explore areas where the two systems may move closer together.

For UK MedTech companies, this shift matters because it suggests a future where meeting UK rules may also require understanding parts of the FDA framework. Many firms already follow EU MDR or UK MDR rules and rely on a UK Responsible Person medical devices arrangement to meet local obligations, but a growing number are now considering whether they need to prepare for FDA compliance to reach the U.S. market or remain competitive as global standards move closer.

For UK-based device manufacturers, this change may influence:
• how products are reviewed before they reach patients
• what safety evidence and documentation must be prepared
• how medical software and hardware are labelled
• what expectations apply after a device is already on the market

This regulatory shift encourages firms to look beyond local requirements and prepare for compliance that stretches across more than one region.

Which Types of Devices are Affected and What “MedTech” Includes

The MedTech sector covers many different products, and several of these may be influenced by how the MHRA and FDA review medical devices. Companies working in this field often deal with a mix of hardware, digital tools and products used in clinical or personal care settings.

MedTech commonly includes:
• Medical devices such as hardware, diagnostic tools and implants
• Medical software and software as a medical device (SaMD)
• Wearable monitoring devices
• Home-use health products
• Certain menstrual products that are treated as medical devices when they meet regulatory criteria

If you work with menstrual products, you can read more in our guide on how these products are classified as medical devices. Different categories may fall under EU MDR, UK MDR or the FDA route depending on where they are sold. For firms operating in more than one region, understanding which framework applies helps shape technical files, safety evidence and labelling plans.

What UK Firms Need to do Now to Stay Compliant

With both the MHRA and FDA reviewing how medical devices are assessed, UK companies may need to strengthen their compliance approach. This includes understanding how the EU MDR, UK MDR and FDA frameworks differ, especially when planning to enter more than one market.

To stay prepared, UK MedTech firms should focus on:

• Understanding the regulatory regimes that apply to their products, including EU MDR, UK MDR and the wider medical device regulation MDR structure used in the EU.
• Carrying out a gap analysis to see where current UK or EU certification may not meet FDA expectations, especially for firms planning on importing medical devices into US markets.
• Reviewing documentation and clinical evidence, ensuring technical files, safety reports and quality system records meet the standards set by each region.
• Updating labels and instructions, especially for medical software and digital devices. You can read more about this in our guide on EU and UK labelling rules for medical software.
• Preparing a compliance plan for medical software, particularly if the product falls under SaMD requirements. Our guide on medical software compliance in the EU and UK explains this in detail.

Challenges for UK Firms Adopting The FDA Compliance Medical Devices

Preparing for FDA requirements can bring several challenges for UK MedTech companies, especially when they already follow EU MDR or UK MDR rules. The FDA pathway can be more demanding in some areas, and firms often need extra planning to meet the expectations for U.S. market entry.

Key challenges include:

• Higher cost, more time and a heavier documentation load. FDA submissions often need detailed technical evidence, clinical data and quality system records that go beyond what is required locally.
  • The need for a U.S.-based authorised contact, as FDA rules expect companies to have someone in the United States who can respond to enquiries and support communication with authorities.
  • Different data expectations and post-market duties, including how incidents are reported, how updates are handled and what monitoring is required once the device is on the market.
  • An effect on manufacturing and supply chain planning, as production sites, testing partners and export routes may need adjustments to match FDA expectations.

How Euverify Helps MedTech Firms With International Compliance

Euverify supports MedTech companies that need practical help managing EU and UK compliance, keeping their documentation organised and ready for future planning. Our work focuses entirely on EU and UK regulatory duties. Euverify does not provide FDA submissions, U.S. Agent services or U.S. regulatory strategy.

Euverify helps with:
• EU and UK compliance support, including an understanding of MDR, UK MDR and the documentation your product must meet
• Document management, giving firms a structured place to build and maintain technical files, clinical evidence and safety reports
• Authorised Representative and UK Responsible Person services, providing the required local contact for regulatory enquiries in each region
• Labelling and safety checks for medical devices and medical software under EU and UK rules

Your Next Steps for Compliance Planning

With the MHRA reviewing parts of the U.S. system, many UK companies are taking time to check whether their current documentation is strong enough for both UK requirements and any future plans they may have for other regions. A simple review helps you understand what is complete, what needs attention and which devices may need clearer evidence based on their classification.

Here is a quick checklist:
• Audit your current EU MDR and UK MDR compliance
• Identify any products that may later need to meet FDA expectations, based on their device class
• Review your documents to see what must be strengthened for EU/UK duties before planning further steps
• Check technical files, clinical evidence and quality system records for accuracy
• Speak to a compliance specialist or Authorised Representative service for support with EU/UK requirements

If you need help reviewing your EU or UK compliance documents, you can reach out to Euverify. We support firms with EU and UK duties, but we do not provide FDA submissions, U.S. Agent services or U.S. regulatory strategy.

FAQs

1. What MHRA changes are prompting interest in FDA compliance?
   The MHRA is exploring ways to recognise parts of the FDA review process, making U.S. approval more relevant for UK firms.

2. How will international reliance routes affect UK device approval?
   Some devices may be able to use FDA evidence to support parts of the UK approval process, reducing repeated work.

3. Which devices benefit most from these US-to-UK pathways?
   Software-based, AI-enabled and digital health devices are likely to benefit the most.

4. What risks must UK firms consider when seeking FDA compliance?
   Stricter evidence demands higher costs, longer timelines and stronger post-market duties.